Masaaki Higashino1, Ryo Kawata2, Koutetsu Lee2, Shuji Nishikawa2, Shimpei Ichihara2, Yasuo Uesugi3. 1. Department of Otolaryngology, Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan. Electronic address: oto061@poh.osaka-med.ac.jp. 2. Department of Otolaryngology, Head and Neck Surgery, Osaka Medical College, Takatsuki, Japan. 3. Department of Radiology, Osaka Medical College, Takatsuki, Japan.
Abstract
OBJECTIVE: We examined the completion rate, safety, and adverse events in patients with T2N0 glottic carcinoma who received chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium). METHODS: In T2N0 glottic carcinoma patients, we retrospectively compared the local control rate and outpatient therapy completion rate between 20 patients who received radiotherapy plus S-1 (S-1 group) and 20 who received radiotherapy alone (RT group). RESULTS: Local recurrence was not detected in any of the 20 subjects from the S-1 group, whereas local recurrence was found in 4 of the 20 subjects (20%) from the RT group (p<0.05). Outpatient treatment was completed by 15 of the 20 subjects from the S-1 group and 17 of the 20 subjects from the RT group (p=0.43). CONCLUSION: We investigated chemoradiotherapy with S-1 in patients who had T2N0 glottic carcinoma and found a higher local control rate when compared with radiotherapy alone as well as comparable safety for outpatient delivery.
OBJECTIVE: We examined the completion rate, safety, and adverse events in patients with T2N0 glottic carcinoma who received chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium). METHODS: In T2N0 glottic carcinomapatients, we retrospectively compared the local control rate and outpatient therapy completion rate between 20 patients who received radiotherapy plus S-1 (S-1 group) and 20 who received radiotherapy alone (RT group). RESULTS: Local recurrence was not detected in any of the 20 subjects from the S-1 group, whereas local recurrence was found in 4 of the 20 subjects (20%) from the RT group (p<0.05). Outpatient treatment was completed by 15 of the 20 subjects from the S-1 group and 17 of the 20 subjects from the RT group (p=0.43). CONCLUSION: We investigated chemoradiotherapy with S-1 in patients who had T2N0 glottic carcinoma and found a higher local control rate when compared with radiotherapy alone as well as comparable safety for outpatient delivery.